MOA of the immunotherapeutic drugs, also called checkpoint inhibitors, is to block PD-1, PD-L1, or CTLA-4 proteins on the immune cells and increase cytotoxic T-cell activity against cancer cells. Here, CTLA4 is linked to cancer.